SAJAZIR is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Cycle Pharmaceuticals Ltd-uk. The primary component is Icatibant Acetate.
Product ID | 70709-013_329a6e8e-da19-491a-acbc-3afd6e40bc1c |
NDC | 70709-013 |
Product Type | Human Prescription Drug |
Proprietary Name | SAJAZIR |
Generic Name | Icatibant |
Dosage Form | Injection |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2021-06-03 |
Marketing Category | ANDA / |
Application Number | ANDA212446 |
Labeler Name | Cycle Pharmaceuticals Ltd-Uk |
Substance Name | ICATIBANT ACETATE |
Active Ingredient Strength | 30 mg/3mL |
Pharm Classes | Bradykinin B2 Receptor Antagonist [EPC], Bradykinin B2 Receptor Antagonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2021-06-03 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
70709-013 | SAJAZIR | ICATIBANT |
0093-3066 | Icatibant | Icatibant |
24201-207 | Icatibant | icatibant |
54092-135 | Icatibant | Icatibant |
63323-574 | Icatibant | Icatibant |
69097-664 | ICATIBANT | ICATIBANT |
71225-114 | Icatibant | Icatibant |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
SAJAZIR 90461564 not registered Live/Pending |
Cycle Pharmaceuticals Ltd. 2021-01-12 |